#61
|
||||
|
||||
Çíà÷èööà, ÿ îøèáàëñÿ ïî ïîâîäó ñëó÷àéíîñòè, íî áûë ïðàâ, ÷òî òî÷êè íå áûëè ïåðâè÷íûìè...
Âîò åùå òàêîé òðàéë: Lancet. 2008 Oct 18;372(9647):1385-93. Epub 2008 Sep 25. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group. BACKGROUND: Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes. METHODS: We did a randomised, double-blind, parallel-group, placebo-controlled trial in 309 centres worldwide. We recruited normoalbuminuric, normotensive, or treated hypertensive people with type 2 diabetes with mild to moderately severe retinopathy and assigned them to candesartan 16 mg once a day or placebo. After a month, the dose was doubled to 32 mg once per day. Investigators and patients were unaware of the treatment allocation status. Progression of retinopathy was the primary endpoint, and regression was a secondary endpoint. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00252694. FINDINGS: 1905 participants (aged 37-75 years) were randomised to candesartan (n=951) or placebo (n=954). 161 (17%) patients in the candesartan group and 182 (19%) in the placebo group had progression of retinopathy by three steps or more on the Early Treatment Diabetic Retinopathy Study scale. The risk of progression of retinopathy was non-significantly reduced by 13% in patients on candesartan compared with those on placebo (hazard ratio [HR] 0.87, 95% CI 0.70-1.08, p=0.20). Regression on active treatment was increased by 34% (1.34, 1.08-1.68, p=0.009). HRs were not attenuated by adjustment for baseline risk factors or changes in blood pressure during the trial. An overall change towards less severe retinopathy by the end of the trial was observed in the candesartan group (odds 1.17, 95% CI 1.05-1.30, p=0.003). Adverse events did not differ between the treatment groups. INTERPRETATION: Treatment with candesartan in type 2 diabetic patients with mild to moderate retinopathy might induce improvement of retinopathy.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#62
|
|||
|
|||
Ýòî èññëåäîâàíèå òîæå ìíå ïîïàäàëîñü, ê ñîæàëåíèþ íå ïîêàçàëî äîñòîâåðíîãî âëèÿíèÿ íà ðåòèíîïàòèþ. Âàäèì Âàëåðüåâè÷, à â Åâðîïå è ÑØÀ ïåíòîêñèôèëèí âîîáùå ïðèìåíÿåòñÿ èëè ýòî îïÿòü íàøà Ðîññèéñêàÿ òðàäèöèÿ (êàê àêòîâåãèí, ñóëîäåêñèä)? ß âñòðå÷àëà íà ôîðóìå âîïðîñû ïî òðåíòàëó, íîîòâåòîâ íå íàøëà.
Åñòü ëè êàêèå òî äîñòîâåðíûå äàííûå ÷òî îí ïîêàçàí/íå ïîêàçàí ïðè äèàáåòè÷åñêîé ðåòèíîïàòèè? |
#63
|
||||
|
||||
Òðåíòàë êàê ëåêàðñòâî èçâåñòåí î÷åíü äàâíî, åùå ñ äîÅÁÌíûõ âðåìåí è âñå èññëåäîâàíèÿ ïî íåìó ïðîâîäèëèñü â òå âðåìåíà, êîãäà ê òðàéëàì áûëè äðóãèå òðåáîâàíèÿ. Ïîýòîìó íà ñåãîäíÿøíèé äåíü íåò íè îäíîãî äîêàçàííîãî ïîêàçàíèÿ äëÿ åãî ïðèìåíåíèÿ â ìåäèöèíå. Èìåþòñÿ îòäåëüíûå ýíòóçèàñòû, êîòîðûå ïîêàçûâàþò åãî ïîëüçó, íàïð. ïðè äèàáåòè÷åñêîé íåôðîïàòèè (ñíèæàåò àëüáóìèíóðèþ) èëè ïðè íåàëêîãîëüíûõ ãåïàòîçàõ.
Åñòü èññëåäîâàíèÿ, ïîêàçûâàþùèå åãî ïîëüçó ïðè äèàáåòè÷åñêîé ðåòèíîïàòèè, íî íåò èññëåäîâàíèé, äîêàçûâàþùèõ åãî ïîëüçó â ïëàíå ïðîãíîçà çàáîëåâàíèÿ.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#64
|
|||
|
|||
Ïðî÷ëà íà ôîðóìå ìíîãî ïîëîæèòåëüíîãî ïðî ïåíòîêñèôèëèí. Ïðèìåíÿåòñÿ îí ïðè ëå÷åíèè äèàáåòè÷åñêîé ðåòèíîïàòèè â Àíãëèè, Ãåðìàíèè, è äðóãèõ ñòðàíàõ çàïàäíîé Åâðîïû è â ÑØÀ? Âõîäèò îí â ãàéäëàéíû ïî ëå÷åíèþ ÄÐ ýòèõ ñòðàí?
|
#65
|
|||
|
|||
ïîñìîòðèòå äèñêóññèþ, íàäåþñü , ññûëêà îòêðîåòñÿ. Èñ÷åðïûâàþùàÿ èíôîðìàöèÿ.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#66
|
|||
|
|||
Öèòàòà:
Öèòàòà:
Ìîå ìíåíèå, âñå åùå ñòàíäàðò "äëÿ äèàáåòè÷åñêîé ðåòèíîïàòèè - êîíòðîëü ãëèêåìèè è ëàçåðíîå ëå÷åíèå ïî ïîêàçàíèÿì". Ïîýòîìó ïîçèòèâ åñòü, íî ñòîèìîñòü... è ïîêàçàíèé íåîáõîäèìî ïðèäåðæèâàòüñÿ. Ñ óâàæåíèåì. P.S. Inñerta - äëÿ îáñóæäåíèÿ: ïî÷åìó óìåíüøàåòñÿ íåîáõîäèìîñòü â ïðîâåäåíèè ËÊ, íî íå âûÿâëÿåòñÿ ðàçíèöû â óõóäøåíèè îñòðîòû çðåíèÿ â ðåçóëüòàòå íàáëþäåíèÿ? |
#67
|
||||
|
||||
Öèòàòà:
|
#68
|
|||
|
|||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îäèí èç ïîñëåäíèõ îáçîðîâ. Ñïàñèáî çà âíèìàíèå ê òåìå. Ñ Íîâûì ãîäîì! |
#69
|
|||
|
|||
òðåáóåò ïàðîëü.... ÷å äåëàòü?
|
#70
|
||||
|
||||
Íàäî çàðåãèñòðèðîâàòüñÿ íà ñàéòå. Çàðåãèñòðèðîâàâøèéñÿ ìîæåò ïîëó÷àòü ðàññûëêó ïî ñïåöèàëüíîñòè è íå òîëüêî!
|